Quidel to Present at Upcoming Conferences
February 22 2021 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a leading provider of
rapid diagnostic testing solutions, cellular-based virology assays
and molecular diagnostic systems, announced today that it will
present at the following upcoming conferences:
- Raymond James & Associates 42nd Annual Institutional
Investors Conference to be held virtually on Tuesday, March 2, 2021
at 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time).
- Barclays Global Healthcare Conference, to be held virtually on
Wednesday, March 10, 2021 at 1:15 p.m. Eastern Time (10:15 a.m.
Pacific Time).
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on the specified
days with question-and-answer sessions scheduled immediately
following each presentation. During the presentations, the company
will discuss business and financial developments and trends. The
company's statements may contain or constitute material information
that has not been previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the links below.
Raymond James:
https://kvgo.com/rjinstitutionalinvestors/quidel-march-2021
Barclays:
https://kvgo.com/2021-global-healthcare-conference/quidel-corp-march-2021
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at
www.quidel.com/ourstory.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210222005805/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024